{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:23:10Z","timestamp":1791062590662,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T00:00:00Z","timestamp":1392336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T00:00:00Z","timestamp":1392336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We assessed the profile and frequency of malignancy subtypes in a large single-centre UK cohort for patients with scleroderma (systemic sclerosis; SSc). We evaluated the cancer risk among SSc patients with different antibody reactivities and explored the temporal association of cancer with the duration between SSc onset and cancer diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of a well-characterised cohort of SSc patients attending a large tertiary referral centre, with clinical data collected from our clinical database and by review of patient records. We evaluated development of all cancers in this cohort, and comparison was assessed with the SSc cohort without cancer. The effect of demographics and clinical details, including antibody reactivities, were explored to find associations relevant to the risk for development of cancer in SSc patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 2,177 patients with SSc, 7.1% had a history of cancer, 26% were positive for anticentromere antibodies (ACAs), 18.2% were positive for anti-Scl-70 antibodies and 26.6% were positive for anti-RNA polymerase III (anti-RNAP) antibody. The major malignancy cancer subtypes were breast (42.2%), haematological (12.3%), gastrointestinal (11.0%) and gynaecological (11.0%). The frequency of cancers among patients with RNAP (14.2%) was significantly increased compared with those with anti-Scl-70 antibodies (6.3%) and ACAs (6.8%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). Among the patients, who were diagnosed with cancer within 36\u00a0months of the clinical onset of SSc, there were more patients with RNAP (55.3%) than those with other autoantibody specificities (ACA\u2009=\u200923.5%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.008; and anti-Scl-70 antibodies\u2009=\u200913.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.002, respectively). Breast cancers were temporally associated with onset of SSc among patients with anti-RNAP, and SSc patients with anti-RNAP had a twofold increased hazard ratio for cancers compared to patients with ACAs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study independently confirms, in what is to the best of our knowledge the largest population examined to date, that there is an association with cancer among SSc patients with anti-RNAP antibodies in close temporal relationship to onset of SSc, which supports the paraneoplastic phenomenon in this subset of SSc cases. An index of cautious suspicion should be maintained in these cases, and investigations for underlying malignancy should be considered when clinically appropriate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar4486","type":"journal-article","created":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T05:01:12Z","timestamp":1392354072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":187,"title":["Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma"],"prefix":"10.1186","volume":"16","author":[{"given":"Pia","family":"Moinzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Chighizola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon H","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"key":"4149_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/SMJ.0b013e31815838ce","volume":"101","author":"M Wooten","year":"2008","unstructured":"Wooten M: Systemic sclerosis and malignancy: a review of the literature. South Med J. 2008, 101: 59-62. 10.1097\/SMJ.0b013e31815838ce.","journal-title":"South Med J"},{"key":"4149_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.autrev.2012.06.003","volume":"12","author":"M Colaci","year":"2013","unstructured":"Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P, Cerri S, Luppi F, Richeldi L, Ferri C: Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev. 2013, 12: 374-379. 10.1016\/j.autrev.2012.06.003.","journal-title":"Autoimmun Rev"},{"key":"4149_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.1780360405","volume":"36","author":"M Abu-Shakra","year":"1993","unstructured":"Abu-Shakra M, Guillemin F, Lee P: Cancer in systemic sclerosis. Arthritis Rheum. 1993, 36: 460-464. 10.1002\/art.1780360405.","journal-title":"Arthritis Rheum"},{"key":"4149_CR4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2169\/internalmedicine.51.7686","volume":"51","author":"A Hashimoto","year":"2012","unstructured":"Hashimoto A, Arinuma Y, Nagai T, Tanaka S, Matsui T, Tohma S, Endo H, Hirohata S: Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med. 2012, 51: 1683-1688. 10.2169\/internalmedicine.51.7686.","journal-title":"Intern Med"},{"key":"4149_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/039463200902200303","volume":"22","author":"B Marasini","year":"2009","unstructured":"Marasini B, Conciato L, Belloli L, Massarotti M: Systemic sclerosis and cancer. Int J Immunopathol Pharmacol. 2009, 22: 573-578.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4149_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.autrev.2012.02.021","volume":"11","author":"\u00c9 Szekanecz","year":"2012","unstructured":"Szekanecz \u00c9, Szamosi S, Horv\u00e1th \u00c1, N\u00e9meth \u00c1, Juh\u00e1sz B, Sz\u00e1nt\u00f3 J, Sz\u00fccs G, Szekanecz Z: Malignancies associated with systemic sclerosis. Autoimmun Rev. 2012, 11: 852-855. 10.1016\/j.autrev.2012.02.021.","journal-title":"Autoimmun Rev"},{"key":"4149_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","volume":"38","author":"P Air\u00f2","year":"2011","unstructured":"Air\u00f2 P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F: Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol. 2011, 38: 1329-1334. 10.3899\/jrheum.101144.","journal-title":"J Rheumatol"},{"key":"4149_CR8","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","volume":"62","author":"AA Shah","year":"2010","unstructured":"Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L: Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies. Arthritis Rheum. 2010, 62: 2787-2795. 10.1002\/art.27549.","journal-title":"Arthritis Rheum"},{"key":"4149_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M: Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012, 71: 710-713. 10.1136\/annrheumdis-2011-200697.","journal-title":"Ann Rheum Dis"},{"key":"4149_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MD.0b013e3181ca14ff","volume":"89","author":"E Trallero-Aragu\u00e1s","year":"2010","unstructured":"Trallero-Aragu\u00e1s E, Labrador-Horrillo M, Selva-O\u2019Callaghan A, Mart\u00ednez MA, Mart\u00ednez-G\u00f3mez X, Palou E, Rodriguez-Sanchez JL, Vilardell-Tarr\u00e9s M: Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010, 89: 47-52. 10.1097\/MD.0b013e3181ca14ff.","journal-title":"Medicine (Baltimore)"},{"key":"4149_CR11","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.","journal-title":"J Rheumatol"},{"key":"4149_CR12","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA: Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001, 28: 1573-1576.","journal-title":"J Rheumatol"},{"key":"4149_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002\/art.1780230510.","journal-title":"Arthritis Rheum"},{"key":"4149_CR14","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/art.22721","volume":"56","author":"L Shand","year":"2007","unstructured":"Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP: Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum. 2007, 56: 2422-2431. 10.1002\/art.22721.","journal-title":"Arthritis Rheum"},{"key":"4149_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","volume":"6","author":"SI Nihtyanova","year":"2010","unstructured":"Nihtyanova SI, Denton CP: Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010, 6: 112-116. 10.1038\/nrrheum.2009.238.","journal-title":"Nat Rev Rheumatol"},{"key":"4149_CR16","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/rheumatology\/kep215","volume":"48","author":"SI Nihtyanova","year":"2009","unstructured":"Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP: A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford). 2009, 48: 1218-1221. 10.1093\/rheumatology\/kep215.","journal-title":"Rheumatology (Oxford)"},{"key":"4149_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005, 35: 35-42. 10.1016\/j.semarthrit.2005.03.005.","journal-title":"Semin Arthritis Rheum"},{"key":"4149_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007, 100: 485-494. 10.1093\/qjmed\/hcm052.","journal-title":"QJM"},{"key":"4149_CR19","volume-title":"Wiley-Blackwell\/BMJ Books","author":"D Altman","year":"2000","unstructured":"Statistics with Confidence: Confidence Intervals and Statistical Guidelines. Edited by: Altman D, Machin D, Bryant T, Gardner S. 2000, Chichester, UK: Wiley-Blackwell\/BMJ Books, 2"},{"key":"4149_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","volume":"52","author":"M Bonifazi","year":"2013","unstructured":"Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A: Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford). 2013, 52: 143-154. 10.1093\/rheumatology\/kes303.","journal-title":"Rheumatology (Oxford)"},{"key":"4149_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s10067-004-0940-5","volume":"23","author":"D Launay","year":"2004","unstructured":"Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B, Hebbar M: Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol. 2004, 23: 516-522. 10.1007\/s10067-004-0940-5.","journal-title":"Clin Rheumatol"},{"key":"4149_CR22","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/01.bor.0000245721.02512.77","volume":"18","author":"SM Levine","year":"2006","unstructured":"Levine SM: Cancer and myositis: new insights into an old association. Curr Opin Rheumatol. 2006, 18: 620-624. 10.1097\/01.bor.0000245721.02512.77.","journal-title":"Curr Opin Rheumatol"},{"key":"4149_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/art.21029","volume":"52","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarc\u00f3n G, Sen\u00e9cal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A: An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005, 52: 1481-1490. 10.1002\/art.21029.","journal-title":"Arthritis Rheum"},{"key":"4149_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001, 357: 96-100. 10.1016\/S0140-6736(00)03540-6.","journal-title":"Lancet"},{"key":"4149_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8","volume":"183","author":"W Chen","year":"1997","unstructured":"Chen W, B\u00f6cker W, Brosius J, Tiedge H: Expression of neural BC200 RNA in human tumours. J Pathol. 1997, 183: 345-351. 10.1002\/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8.","journal-title":"J Pathol"},{"key":"4149_CR26","doi-asserted-by":"publisher","first-page":"48182","DOI":"10.1074\/jbc.M201333200","volume":"277","author":"ZA Felton-Edkins","year":"2002","unstructured":"Felton-Edkins ZA, White RJ: Multiple mechanisms contribute to the activation of RNA polymerase III transcription in cells transformed by papovaviruses. J Biol Chem. 2002, 277: 48182-48191. 10.1074\/jbc.M201333200.","journal-title":"J Biol Chem"},{"key":"4149_CR27","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1128\/MCB.19.7.4927","volume":"19","author":"CG Larminie","year":"1999","unstructured":"Larminie CG, Sutcliffe JE, Tosh K, Winter AG, Felton-Edkins ZA, White RJ: Activation of RNA polymerase III transcription in cells transformed by simian virus 40. Mol Cell Biol. 1999, 19: 4927-4934.","journal-title":"Mol Cell Biol"},{"key":"4149_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrm1551","volume":"6","author":"RJ White","year":"2005","unstructured":"White RJ: RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol. 2005, 6: 69-78. 10.1038\/nrm1551.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4149_CR29","doi-asserted-by":"publisher","first-page":"14917","DOI":"10.1073\/pnas.0702909104","volume":"104","author":"NS Kenneth","year":"2007","unstructured":"Kenneth NS, Ramsbottom BA, Gomez-Roman N, Marshall L, Cole PA, White RJ: TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci U S A. 2007, 104: 14917-14922. 10.1073\/pnas.0702909104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4149_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-1-4419-5774-0_6","volume-title":"Scleroderma: From Pathogenesis to Comprehensive Management","author":"RT Domsic","year":"2012","unstructured":"Domsic RT, Medsger TA: Disease subsets in clinical practice. Scleroderma: From Pathogenesis to Comprehensive Management. Edited by: Varga J, Denton CP, Wigley FM. 2012, New York: Springer, 45-52."},{"key":"4149_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12016-012-8331-1","volume":"43","author":"P Moinzadeh","year":"2012","unstructured":"Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP: Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012, 43: 249-255. 10.1007\/s12016-012-8331-1.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4149_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T","volume":"76","author":"AK Rosenthal","year":"1995","unstructured":"Rosenthal AK, McLaughlin JK, Gridley G, Nyr\u00e9n O: Incidence of cancer among patients with systemic sclerosis. Cancer. 1995, 76: 910-914. 10.1002\/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T.","journal-title":"Cancer"},{"key":"4149_CR33","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/art.1780281204","volume":"28","author":"AD Roumm","year":"1985","unstructured":"Roumm AD, Medsger TA: Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum. 1985, 28: 1336-1340. 10.1002\/art.1780281204.","journal-title":"Arthritis Rheum"},{"key":"4149_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00296-001-0141-3","volume":"21","author":"Y Yang","year":"2001","unstructured":"Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T: Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int. 2001, 21: 106-111. 10.1007\/s00296-001-0141-3.","journal-title":"Rheumatol Int"},{"key":"4149_CR35","first-page":"1136","volume":"12","author":"M Peters-Golden","year":"1985","unstructured":"Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM: Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985, 12: 1136-1139.","journal-title":"J Rheumatol"},{"key":"4149_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2214\/ajr.140.5.927","volume":"140","author":"RD Halpert","year":"1983","unstructured":"Halpert RD, Laufer I, Thompson JJ, Feczko PJ: Adenocarcinoma of the esophagus in patients with scleroderma. AJR Am J Roentgenol. 1983, 140: 927-930. 10.2214\/ajr.140.5.927.","journal-title":"AJR Am J Roentgenol"},{"key":"4149_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0002-9343(87)90376-7","volume":"82","author":"DA Katzka","year":"1987","unstructured":"Katzka DA, Reynolds JC, Saul SH, Plotkin A, Lang CA, Ouyang A, Jimenez S, Cohen S: Barrett\u2019s metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med. 1987, 82: 46-52. 10.1016\/0002-9343(87)90376-7.","journal-title":"Am J Med"},{"key":"4149_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ard.62.8.728","volume":"62","author":"CL Hill","year":"2003","unstructured":"Hill CL, Nguyen AM, Roder D, Roberts-Thomson P: Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis. 2003, 62: 728-731. 10.1136\/ard.62.8.728.","journal-title":"Ann Rheum Dis"},{"key":"4149_CR39","first-page":"65","volume":"2013","author":"A Onishi","year":"1913\u20131921","unstructured":"Onishi A, Sugiyama D, Kumagai S, Morinobu A: Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 1913\u20131921, 2013: 65-","journal-title":"Arthritis Rheum"},{"key":"4149_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/rheumatology\/28.1.65","volume":"28","author":"AM Forbes","year":"1989","unstructured":"Forbes AM, Woodrow JC, Verbov JL, Graham RM: Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol. 1989, 28: 65-69. 10.1093\/rheumatology\/28.1.65.","journal-title":"Br J Rheumatol"},{"key":"4149_CR41","first-page":"197","volume":"19","author":"G Hassett","year":"2001","unstructured":"Hassett G, Harnett P, Manolios N: Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol. 2001, 19: 197-200.","journal-title":"Clin Exp Rheumatol"},{"key":"4149_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1196\/annals.1351.023","volume":"1069","author":"L Mirone","year":"2006","unstructured":"Mirone L, Barini A: Androgen and prolactin (Prl) levels in systemic sclerosis (SSc): relationship to disease severity. Ann NY Acad Sci. 2006, 1069: 257-262. 10.1196\/annals.1351.023.","journal-title":"Ann NY Acad Sci"},{"key":"4149_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/rheumatology\/36.4.426","volume":"36","author":"RH Straub","year":"1997","unstructured":"Straub RH, Zeuner M, Lock G, Sch\u00f6lmerich J, Lang B: High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol. 1997, 36: 426-432. 10.1093\/rheumatology\/36.4.426.","journal-title":"Br J Rheumatol"},{"key":"4149_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejphar.2011.03.040","volume":"660","author":"R L\u00f3pez-Marure","year":"2011","unstructured":"L\u00f3pez-Marure R, Contreras PG, Dillon JS: Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur J Pharmacol. 2011, 660: 268-274. 10.1016\/j.ejphar.2011.03.040.","journal-title":"Eur J Pharmacol"},{"key":"4149_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.arcmed.2010.05.009","volume":"41","author":"N Qian","year":"2010","unstructured":"Qian N, Ueno T: Is dysfunction of caveolin-1 a link between systemic sclerosis and breast cancer, opening a window on both etiologies?. Arch Med Res. 2010, 41: 297-301. 10.1016\/j.arcmed.2010.05.009.","journal-title":"Arch Med Res"},{"key":"4149_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/03009740902758875","volume":"38","author":"W Lei","year":"2009","unstructured":"Lei W, Luo Y, Lei W, Luo Y, Yan K, Zhao S, Li Y, Qiu X, Zhou Y, Long H, Zhao M, Liang Y, Su Y, Lu Q: Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol. 2009, 38: 369-374. 10.1080\/03009740902758875.","journal-title":"Scand J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4486\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:11:57Z","timestamp":1728367917000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,2]]}},"alternative-id":["4149"],"URL":"https:\/\/doi.org\/10.1186\/ar4486","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,14]]},"assertion":[{"value":"10 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R53"}}